Pliant Therapeutics, Inc. (NasdaqGS: PLRX)
Health Care · Pharmaceuticals · US
$1.02
-1.45% today · -31.5% 1Y
Pliant Therapeutics, Inc. (NasdaqGS: PLRX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $63.16M and employs 49 people.
Over the last twelve months the share price has lost 31.5%, trading between 0.97 and 1.95.
Tweenvest scores Pliant Therapeutics, Inc. across four factors: quality 39/100, value 39/100. Its strongest factor is quality.
PLRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $63.16M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.50
- Dividend yield
- —
- Beta (5Y)
- 1.28
- 52-week high
- $1.95
- 52-week low
- $0.97
- Avg volume (3M)
- —
- Shares outstanding
- 61.92M
- Employees
- 49
- Next earnings
- —
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
- ISIN
- US7291391057
- Founded
- 2015
- Listed since
- Jun 3, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Kukje Pharma Co., Ltd.KOSE: A002720 | $64.68M | ₩4,270.00 | +30.18% |
| Kubota Pharmaceutical Holdings Co., Ltd.TSE: 4596 | $64.51M | ¥63.00 | -5.97% |
| TSH Biopharm Corporation LimitedTPEX: 8432 | $63.89M | NT$53.20 | +4.11% |
| Sam-A Pharm. Co., LtdKOSDAQ: A009300 | $63.47M | ₩13,980.00 | +0.94% |
| Choong Ang Vaccine Laboratory Co., Ltd.KOSDAQ: A072020 | $63.07M | ₩9,160.00 | +0.11% |
| DK Life Science Co., Ltd.KOSDAQ: A303810 | $63.05M | ₩2,650.00 | -5.53% |
| Recce Pharmaceuticals LtdASX: RCE | $62.95M | AU$0.30 | -9.23% |
| InterCure Ltd.TASE: INCR | $62.72M | ₪16.22 | -3.97% |
Figures last refreshed Oct 11, 2026.